natgillin/translations-raw huggingface dataset:
Caution is therefore needed when anticoagulants such as coumarin, heparin, dipyridamole, acetylsalicylic acid or nonsteroidal anti-inflammatory drugs are given concomitantly.
Zato je potrebna previdnost pri sočasnem dajanju antikoagulantov, kot so kumarin, heparin, dipiridamol, acetilsalicilna kislina ali nesteroidna protivnetna zdravila.
Caution is to be taken in patients with known hypersensitivity to other bisphosphonates.
Previdnost je potrebna pri bolnikih z znano preobčutljivostjo za druge difosfonate.
Caution is to be taken in patients with known hypersensitivity to other bisphosphonates.
Pri bolnikih z znano preobčutljivostjo za druge difosfonate je potrebna previdnost.
Caution is warranted
Previdnost je utemeljena, saj
Caution is warranted and
Potrebna je previdnost in
Caution is warranted and
Pri sočasni uporabi z okrepljenim
Caution is warranted and
Pri sočasni uporabi z zdravilom
Caution is warranted and clinical
Potrebna je previdnost in klinično
Caution is warranted and clinical
Pri kombiniranju z okrepljenim
Caution is warranted and clinical monitoring is
Potrebna je previdnost in klinično spremljanje.
Caution is warranted and clinical monitoring is
Potrebna je previdnost in priporočljivo je klinično spremljanje bolnika.
Caution is warranted and clinical monitoring is recommended upon co-administration of Genvoya.
Pri sočasni uporabi teh učinkovin z zdravilom Genvoya je potrebna previdnost, priporoča pa se tudi klinično spremljanje.
Caution is warranted and clinical monitoring is recommended upon co-administration of Stribild.
Pri sočasni uporabi teh učinkovin z zdravilom Stribild je potrebna previdnost, priporoča pa se tudi klinično spremljanje.
Caution is warranted and clinical monitoring is recommended when combined with boosted PREZISTA.
Pri sočasni uporabi z okrepljenim zdravilom PREZISTA je potrebna previdnost in klinično spremljanje bolnika.
Caution is warranted and clinical monitoring is recommended, when co-administration of clotrimazole is required.
Kadar je potrebna sočasna uporaba s klotrimazolom, je potrebna previdnost in klinično spremljanje bolnika.
Caution is warranted and clinical monitoring of
Potrebna je previdnost in priporočljivo je klinično spremljanje bolnika.
Caution is warranted and clinical monitoring of patients is recommended.
natančno klinično spremljanje in
Caution is warranted and clinical monitoring of patients is recommended.
Potrebna je previdnost, priporočljivo
Caution is warranted if mild CYP3A inducers are used concomitantly with Bosulif.
Pri sočasni uporabi zdravila Bosulif skupaj z blagimi induktorji CYP3A je potrebna previdnost.
Caution is warranted if Onglyza is used in patients who have known risk factors for hospitalization for heart failure, such as a history of heart failure or moderate to severe renal impairment.
Previdnost je potrebna, če je zdravilo Onglyza uporabljeno pri bolnikih z znanimi dejavniki tveganja za hospitalizacijo zaradi srčnega popuščanja, npr. pri bolnikih z anamnezo srčnega popuščanja ali z zmerno do hudo okvaro ledvic.
Caution is warranted if Qtern is used in patients who have known risk factors for hospitalization for heart failure, such as a history of heart failure or moderate to severe renal impairment.
Zdravilo Qtern je treba uporabljati previdno pri bolnikih z znanimi dejavniki tveganja za hospitalizacijo zaradi srčnega popuščanja, npr. pri bolnikih z anamnezo srčnega popuščanja ali z zmerno do hudo okvaro ledvic.
Caution is warranted if this medicinal product is used in patients who have known risk factors for hospitalization for heart failure, such as a history of heart failure or moderate to severe renal impairment.
Previdnost je potrebna, če je to zdravilo uporabljeno pri bolnikih z znanimi dejavniki tveganja za hospitalizacijo zaradi srčnega popuščanja, npr. pri bolnikih z anamnezo srčnega popuščanja ali z zmerno do hudo okvaro ledvic.
Caution is warranted if Tyverb is prescribed to patients with moderate or severe hepatic impairment (see sections 4.2 and 5.2).
Pri predpisovanju zdravila Tyverb bolnikom z zmerno ali s hudo okvaro jeter je potrebna previdnost (glejte poglavji 4.2 in 5.2).
Caution is warranted.
Potrebna je previdnost.
Caution must also be exercised if Agenerase is used concurrently with atorvastatin, which is metabolized to a lesser extent by CYP3A4.
Previdnost je potrebna tudi ob sočasni uporabi zdravila Agenerase in atorvastatina; presnova slednjega je sicer manj odvisna od CYP3A4.
Caution must be demonstrated if the patient:
Zdravnik mora biti pozoren, če:
Caution must be exercised in these patients and dose adjustment may be necessary (see section 5.2).
Pri teh bolnikih je potrebna previdnost in morebitna prilagoditev odmerka (glejte poglavje 5.2).
Caution on the choice of antibiotic agent and dose should be taken when treating patients with late-onset ventilator-associated pneumonia (> 5 days hospitalisation) and in other nosocomial pneumonia cases where pathogens with decreased susceptibility are suspected or confirmed, such as
Previdnost pri izbiri antibiotika in odmerku se priporoča pri zdravljenju bolnikov s poznim nastopom pljučnice zaradi uporabe respiratorja (> 5 dnevna hospitalizacija) in drugih bolnišničnih pljučnic, kjer se sumi na ali so potrjeni povzročitelji z zmanjšano občutljivostjo, kot npr.
Caution required with concomitant use CYP3A4 inhibitors
Med sočasno uporabo je potrebna previdnost Zaviralci CYP3A4
Caution required with concomitant use P-gp interactions
Zdravila, pri katerih je potrebna previdnost pri sočasni uporabi Interakcije povezane s P-gp
Caution should also be exercised in the following cases: Hypersensitivity reactions
Previdni morate biti tudi v naslednjih primerih: Preobčutljivostne reakcije
Caution should also be taken with co-administration with beta-blockers or digoxin.
Previdnost je potrebna tudi med sočasno uporabo z zaviralci beta ali digoksinom.
Caution should be
Previdnost je potrebna pri
Caution should be
Pri uporabi kombinacij
Caution should be exercised and a reduction of the starting dose of Iclusig to 30 mg should be considered with concurrent use of strong CYP3A inhibitors such as clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit juice.
Pri sočasni uporabi močnih zaviralcev CYP3A, kot so klaritromicin, indinavir, itrakonazol, ketokonazol, nefazodon, nelfinavir, ritonavir, sakvinavir, telitromicin, troleandomicin, vorikonazol in sok grenivke, je potrebna previdnost, razmisliti pa je treba tudi o zmanjšanju začetnega odmerka zdravila Iclusig na 30 mg,
Caution should be exercised and a reduction of the starting dose of Iclusig to 30 mg should be considered with concurrent use of strong CYP3A inhibitors such as clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit juice.
Pri sočasni uporabi močnih zaviralcev CYP3A, kot so klaritromicin, indinavir, itrakonazol, ketokonazol, nefazodon, nelfinavir, ritonavir, sakvinavir, telitromicin, troleandomicin, vorikonazol in sok grenivke, je potrebna previdnost, razmisliti pa je treba tudi o zmanjšanju začetnega odmerka zdravila Iclusig na 30 mg.
Caution should be exercised and careful assessment of therapeutic response and tolerability should be made before increasing to daily dosing after one week.
Preden odmerek po enem tednu previdno povečamo na dnevni odmerek vsak dan, je treba natančno oceniti odzivanje na zdravljenje in prenašanje.
Caution should be exercised and careful assessment of therapeutic response and tolerability should be made before increasing to daily dosing after one week.
Preden odmerek po enem tednu previdno povečamo na dnevni odmerek, je treba natančno oceniti odzivanje na zdravljenje in prenašanje.
Caution should be exercised and follow-up organised in patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicinal products.
Pri bolnikih s zvišano ALT in/ali AST, bolnikih z znaki in simptomi okvarjenega delovanja jeter, bolnikih s prej obstoječimi stanji, povezanimi z omejeno jetrno funkcionalno rezervo, in pri bolnikih, ki se zdravijo s potencialno hepatotoksičnimi zdravili, je potrebna previdnost.
Caution should be exercised and follow-up organised in patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines.
Pri bolnikih s zvišano ALT in/ali AST, bolnikih z znaki in simptomi okvarjenega delovanja jeter, bolnikih s prej obstoječimi stanji, povezanimi z omejeno jetrno funkcionalno rezervo, in pri bolnikih, ki se zdravijo s potencialno hepatotoksičnimi zdravili, je potrebna previdnost in nadaljnje zdravljenje.
Caution should be exercised and follow-up organised in patients with elevated ALT and/or AST,in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines.
Pri bolnikih s zvišano ALT in/ali AST, bolnikih z znaki in simptomi okvarjenega delovanja jeter, bolnikih s prej obstoječimi stanji, povezanimi z omejeno jetrno funkcionalno rezervo, in pri bolnikih, ki se zdravijo s potencialno hepatotoksičnimi zdravili, sta potrebna previdnost in nadaljnje spremljanje.
Caution should be exercised and follow-up organized in patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines.
Pri bolnikih s zvišano ALT in/ali AST, bolnikih z znaki in simptomi okvarjenega delovanja jeter, bolnikih s prej obstoječimi stanji, povezanimi z omejeno jetrno funkcionalno rezervo, in pri bolnikih, ki se zdravijo s potencialno hepatotoksičnimi zdravili, je potrebna previdnost.
Caution should be exercised and patients closely observed for bosentan- related toxicity.
Potrebna je previdnost, bolnike pa je treba skrbno spremljati zaradi toksičnosti, povezane z bosentanom.
Caution should be exercised and reduced doses should be considered when lopinavir/ritonavir is co- administered with rosuvastatin (see section 4.4).
Sočasna uporaba lopinavirja/ritonavirja s tadalafilom ni priporočljiva.
Caution should be exercised as cases of late occurrence of first neurological events in the second cycle have been observed.
Potrebna je previdnost, saj so opazili primere poznega pojava prvih nevroloških dogodkov v drugem ciklusu.
Caution should be exercised due to the risk of increased axitinib plasma concentrations in patients taking strong inhibitors of these isozymes.
Zaradi tveganja, da se plazemske koncentracije aksitiniba pri bolnikih, ki jemljejo močne zaviralce teh izoencimov, povečajo, je potrebna previdnost.
Caution should be exercised if mild CYP3A inhibitors are used concomitantly with bosutinib.
Sočasna uporaba blagih zaviralcev CYP3A skupaj z bosutinibom zahteva previdnost.
Caution should be exercised if patients have moderate hepatic disease
Pri bolnikih z zmerno okvaro jeter je potrebna previdnost.
Caution should be exercised in
Bolniki, ki jemljejo vzdrževalni
Caution should be exercised in
lopinavirjem/ritonavirjem, je
Caution should be exercised in
Pri uporabi afatiniba z zdravilom
Caution should be exercised in
Prilagoditev odmerka ni potrebna.
Caution should be exercised in administering carbamazepine or phenobarbital with lopinavir/ritonavir.
lopinavirja/ritonavirja in digoksina je potrebna previdnost.
Caution should be exercised in administering ceritinib with Kaletra.
Pri uporabi ceritiniba z zdravilom Kaletra je potrebna previdnost.
Caution should be exercised in administering ceritinib with Kaletra.
V primeru sočasne uporabe zdravila Kaletra in digoksina je potrebna previdnost.
Caution should be exercised in administering clarithromycin with Kaletra to patients with impaired hepatic or renal function.
Pri bolnikih z okvarjenim delovanjem jeter ali ledvic je treba klaritromicin hkrati z zdravilom Kaletra uporabljati previdno.
Caution should be exercised in administering crizotinib in combination with medicinal products that are predominantly metabolised by these enzymes.
Potrebna je previdnost, kadar se krizotinib uporablja skupaj z zdravili, ki se presnavljajo pretežno s temi encimi.
Caution should be exercised in co- administering CYP3A4 inhibitors (e.g. ketoconazole, macrolide antibiotics, diltiazem) with tolvaptan (see section 4.4).
Pri sočasni uporabi zaviralcev CYP3A4 (npr. ketokonazola, makrolidnih antibiotikov, diltiazema) s tolvaptanom je potrebna previdnost (glejte poglavje 4.4).
Caution should be exercised in co-administering CYP3A4 inducers (e.g. rifampicin, barbiturates) with tolvaptan.
Pri sočasni uporabi induktorjev CYP3A4 (npr. rifampicina, barbituratov) s tolvaptanom je potrebna previdnost.
Caution should be exercised in coadministration of fesoterodine with other antimuscarinics and medicinal products with anticholinergic properties (e.g. amantadine, tri-cyclic antidepressants, certain neuroleptics ) as this may lead to more pronounced therapeutic- and side-effects (e.g. constipation, dry mouth, drowsiness, urinary retention).
Pri sočasni uporabi fesoterodina in drugih antimuskarinikov ter zdravil z antiholinergičnimi lastnostmi (npr. amantadin, triciklični antidepresivi, nekateri nevroleptiki) je potrebna previdnost, ker lahko povzroči bolj izražene terapevtske učinke in neželene učinke (npr. zaprtje, suha usta, dremavost, retencijo urina).
Caution should be exercised in patients at risk, such as the elderly, patients with cirrhosis of the liver or patients concomitantly treated with medications known to cause hyponatraemia.
Previdnost je potrebna pri ogroženih bolnikih, kot so starejši bolniki ali bolniki s cirozo jeter oziroma bolniki, sočasno zdravljeni z zdravili, za katere je znano, da povzročajo hiponatriemijo.
Caution should be exercised in patients on 5- or 8-methoxypsoralen (5 and 8-MOP), which increases melatonin levels by inhibiting its metabolism.
Pri bolnikih, ki se zdravijo s 5- ali 8-metoksipsoralenom (5 in 8-MOP) je potrebna previdnost, saj dviguje ravni melatonina z zaviranjem njegove presnove.
Caution should be exercised in patients on cimetidine a CYP2D inhibitor, which increases plasma melatonin levels, by inhibiting its metabolism.
Previdnost je potrebna pri bolnikih, ki se zdravijo s cimetidinom, zaviralcem CYP2D, ki povečuje ravni melatonina v plazmi z zaviranjem njegove presnove.
Caution should be exercised in patients on fluvoxamine, which increases melatonin levels (by 17-fold higher AUC and a 12-fold higher serum Cmax) by inhibiting its metabolism by hepatic cytochrome P450 (CYP) isozymes CYP1A2 and CYP2C19.
Previdnost je potrebna pri bolnikih, ki se zdravijo s fluvoksaminom, ki povišuje ravni melatonina (za 17-krat višji AUC in 12-krat višji serum Cmax) z zaviranjem njegove presnove preko izocimov jetrnega citokroma P450 (CYP) CYP1A2 in CYP2C19.
Caution should be exercised in patients on oestrogens (e.g. contraceptive or hormone replacement therapy), which increase melatonin levels by inhibiting its metabolism by CYP1A1 and CYP1A2.
Previdnost je potrebna pri bolnikih, ki jemljejo estrogen (npr. kontracepcijska sredstva ali nadomestno hormonsko terapijo), saj ta zvišuje raven melatonina z zaviranjem njegove presnove s CYP1A1 in CYP1A2.
Caution should be exercised in patients receiving concurrent administration of ONIVYDE with irradiation.
Pri bolnikih, ki hkrati prejemajo zdravilo ONIVYDE in so obsevani, je potrebna previdnost.
Caution should be exercised in patients receiving medicinal products with a narrow therapeutic index or medicinal products that require careful clinical monitoring.
Previdnost je potrebna pri bolnikih, zdravljenih z zdravili, ki imajo ozek terapevtski indeks ali zahtevajo skrbno klinično spremljanje.
Caution should be exercised in patients receiving spinal and (or) epidural anaesthesia.
Pri bolnikih, ki prejemajo spinalno in (ali) epiduralno anestezijo, je potrebna previdnost.
Caution should be exercised in patients who are taking EXJADE in combination with substances that have known ulcerogenic potential, such as NSAIDs, corticosteroids, or oral bisphosphonates, in patients receiving anticoagulants and in patients with platelet counts below 50,000/mm3 (50 x 109/l) (see section 4.5).
Previdnost je potrebna pri bolnikih, ki jemljejo zdravilo EXJADE v kombinaciji z zdravilnimi učinkovinami, za katere je znano, da lahko povzročajo ulkuse, kot so nesteroidna protivnetna zdravila, kortikosteroidi ali peroralni difosfonati, pri bolnikih, ki prejemajo antikoagulante, in pri bolnikih s koncentracijo trombocitov, ki je nižja od 50.000/mm3 (50 x 109/l) (glejte poglavje 4.5).
Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of pregabalin misuse, abuse or dependence (development of tolerance, dose escalation, drug--seeking behaviour have been reported).
Pri bolnikih z anamnezo zlorabe prepovedanih snovi je potrebna previdnost in jih je potrebno nadzirati glede možnih simptomov nepravilne uporabe, zlorabe ali odvisnosti od pregabalina (poročali so o razvoju tolerance, povečevanju odmerka in povpraševanju po zdravilu).
Caution should be exercised in patients with hepatic impairment (bilirubin > 2 times upper limit of normal [ULN]; transaminases > 5 times ULN).
Previdnost je potrebna pri bolnikih z jetrno okvaro (bilirubin > 2-kratna zgornja meja normalnih vrednosti [ULN]; transaminaze > 5-kratna ULN).
Caution should be exercised in patients with moderate renal impairment.
Pri bolnikih z zmerno okvarjenim delovanjem ledvic je potrebna previdnost.
Caution should be exercised in patients with previous autoimmune conditions other than MS, although available data suggests there is no worsening of pre-existing autoimmune conditions after alemtuzumab treatment.
Previdnost je potrebna pri bolnikih, ki so predhodno zboleli za avtoimunskimi stanji razen MS, čeprav razpoložljivi podatki kažejo, da se predhodna avtoimunska stanja po zdravljenju z alemtuzumabom ne poslabšajo.
Caution should be exercised in patients with recent or ongoing clinically significant gastrointestinal disorder (see section 4.4).
Pri bolnikih z nedavnimi ali trenutno prisotnimi klinično pomembnimi boleznimi prebavil je potrebna previdnost (glejte poglavje 4.4).
Caution should be exercised in patients with relevant cardiac disorders (see section 4.4).
Pri bolnikih s klinično pomembnimi boleznimi srca je potrebna previdnost (glejte poglavje 4.4).
Caution should be exercised in patients with risk factors for QT prolongation , including patients with a personal or family history of QT prolongation, congestive heart failure, bradyarrhythmias and electrolyte abnormalities.
Previdnost je potrebna pri bolnikih z dejavniki tveganja za podaljšan interval QT, vključno z bolniki, ki imajo podaljšani QT interval v anamnezi ali družinski anamnezi, kongestivno srčno popuščanje, bradiaritmije in elektrolitsko neravnovesje.
Caution should be exercised in patients with risk factors for QT prolongation, including patients risk factors for QT prolongation, including patients with a personal or family history of QT prolongation, congestive heart failure, bradyarrhythmias and electrolyte abnormalities.
Previdnost je potrebna pri bolnikih z dejavniki tveganja za podaljšan interval QT, vključno z bolniki, ki imajo podaljšani QT interval v anamnezi ali družinski anamnezi, kongestivno srčno popuščanje, bradiaritmije in elektrolitsko neravnovesje.
Caution should be exercised in prescribing and infusing IVIg in obese patients and in patients with pre-existing risk factors for thrombotic events (such as advanced age, hypertension, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilisation, severely hypovolemic patients, and patients with diseases which increase blood viscosity).
Ig predpisujete in infundirate bolnikom s čezmerno telesno maso in bolnikom, pri katerih obstajajo dejavniki tveganja za trombotične dogodke (kot so visoka starost, hipertenzija, sladkorna bolezen in žilna obolenja ali trombotične epizode v anamnezi, bolniki s pridobljenimi ali prirojenimi trombofilnimi motnjami, bolniki z dolgo dobo imobilizacije, bolniki z resno hipovolemijo in bolnikih z boleznimi, ki povečujejo viskoznost krvi).
Caution should be exercised in prescribing and infusing IVIg in obese patients and in patients with pre-existing risk factors for thrombotic events (such as advanced age, hypertension, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilisation, severely hypovolemic patients, and patients with diseases which increase blood viscosity).
Ig predpisujete in infundirate bolnikom s čezmerno telesno maso in bolnikom, pri katerih obstajajo dejavniki tveganja za trombotične dogodke (kot so visoka starost, hipertenzija, sladkorna bolezen in žilna obolenja ali trombotične epizode v anamnezi, bolniki s pridobljenimi ali prirojenimi trombofilnimi motnjami, bolniki z dolgo dobo imobilizacije, bolnikih z resno hipovolemijo in bolniki z boleznimi, ki povečujejo viskoznost krvi).
Caution should be exercised in prescribing and infusion of IVIg in obese patients and in patients with pre-existing risk factors for thrombotic events (such as a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, hypertension, use of estrogens, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, hypercoagulable disorders, patients with prolonged periods of immobilisation, severely hypovolemic patients, patients with diseases which increase blood viscosity, patients with indwelling vascular catheters and patients with high dose and rapid infusion).
Intravenske imunoglobulinske pripravke morate predpisovati in infundirati previdno pri bolnikih s čezmerno telesno maso, bolnikih s prisotnimi dejavniki tveganja za trombotične dogodke (kot so ateroskleroza v anamnezi, več kardiovaskularnih dejavnikov tveganja, višja starost, slabši minutni volumen srca, hipertenzija, uporaba estrogenov, sladkorna bolezen in bolezni ožilja ali trombotične epizode v anamnezi, bolnikih s pridobljenimi ali dednimi trombofilnimi boleznimi, boleznimi hiperkoagulacije, dolgotrajno imobiliziranih bolnikih, močno hipovolemičnih bolnikih, bolnikih z boleznimi, ki povečajo viskoznost krvi, bolnikih s stalnim vaskularnim katetrom ter bolnikih z visokimi odmerki in hitrim infundiranjem).
Caution should be exercised in the administration of Dacogen to patients with hepatic impairment and patients should be monitored closely (see sections 4.2 and 5.2).
Pri odmerjanju zdravila Dacogen bolnikom z okvaro jeter je potrebna previdnost, bolnike pa je treba skrbno spremljati (glejte poglavji 4.2 in 5.2).
Caution should be exercised in the administration of Dacogen to patients with severe renal impairment (Creatinine Clearance [CrCl] < 30 ml/min) and these patients should be monitored closely (see section 4.2).
Pri odmerjanju zdravila Dacogen bolnikom s hudo okvaro ledvic (z očistkom kreatinina [CrCl] <30 ml/min) je potrebna previdnost, bolnike pa je treba skrbno spremljati (glejte poglavje 4.2).
Caution should be exercised in the treatment of patients with renal impairment and the dose should be adjusted according to creatinine clearance (CLCR) as follows:
Pri zdravljenju bolnikov z ledvično okvaro je potrebna previdnost, odmerek pa je treba prilagoditi glede na kreatininski očistek (CLCR) na naslednji način:
Caution should be exercised in these patients.
Pri teh bolnikih je potrebna previdnost.